drugset

drugset / Trial / NCT03285412

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412 ↗

Phase 2 Active not recruiting 120 enrolled Massachusetts General Hospital Novartis · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib

Timeline

Start: 2017-12-12
Primary completion: 2026-04
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ribociclib	Small molecule	—	—

Indications